Sq

Thrice weekly

12 weeks

versus sequential therapy in untreated, but symptomatic, patients with CLL. One hundred and four patients were randomized to either FLU 25 mg/m2 daily for 5 days monthly for 6 months, or FLU at the same dose and schedule plus rituximab 375 mg/m2 on day 1 and 4 of the first cycle, then on day 1 of the subsequent 5 cycles. All patients were then treated with rituximab 375 mg/m2 weekly for 4 weeks as consolidation therapy. The remission rate for patients enrolled on the concurrent arm was 90%, while the remission rate was 77% for patients on the sequential arm; there was no difference in either PFS or overall survival.7 Furthermore, patients receiving the concurrent regimen experienced more grade 3 or 4 neutropenia compared to those on the sequential arm (74% vs 41%, respectively) and grade 3 or 4 infusion-related toxicity (20% vs 0%, respectively).

0 0

Post a comment